Tyme Technologies, Inc. (NASDAQ:TYME)
Industry: Healthcare

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.

Current Quote*
Last: $1.420
Change: 0.040
Book: $13.084
Volume: 65,641

As Of: 10/22 13:03 ET
*Quotes delayed by 20min.

Graphs for TYME


3 Month Graph


6 Month Graph


1 Year Graph